Gene-expression signatures in oncology diagnostics

Pharmacogenomics

Volumn 7, Issue 8, 2006, Pages 1167-1173

  Mazumder, Abhijit ^a   Wang, Yixin ^a  

^a Johnson and Johnson   (United States)

Author keywords

Diagnostics; Gene expression profiling; Gene signature; Molecular assay; Prognostics

Indexed keywords

RNA;

BREAST CANCER; CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; COLON CANCER; DNA MICROARRAY; FAMILIAL CANCER; FREEZE DRYING; GENE EXPRESSION PROFILING; HEALTH CARE FACILITY; HUMAN; LYMPHOMA; PROGNOSIS; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA ISOLATION; STANDARDIZATION; TISSUE PRESERVATION; VALIDATION PROCESS;

GENE EXPRESSION PROFILING; HUMANS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RNA; SPECIMEN HANDLING;

EID: 33845871734     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.7.8.1167     Document Type: Review

References (53)

1. Godfrey TE, Kim SH, Chavira M et al: Quantitative mRNA expression analysis from formalin-fixed, paraffin-embedded tissues using 5′ nuclease quantitative reverse transcription-polymerase chain reaction. J. Mol. Diagn 2, 84-91 (2000).
2. Talantov D, Baden J, Jatkoe T et al.: A quantitative reverse transcriptase polymerase chain reaction assay to identify metastatic carcinoma tissue of origin. J. Mol. Diagn. (2006) (In press).
3. Chowdary D, Lathrop J, Skelton J et al.: Prognostic gene expression signatures can be measured in tissues collected in RNAlater preservative. J. Mol. Diagn. 8, 31-39 (2006).
4. Hede K: NCI's National Biospecimen Network: too early or too late? J. Natl Cancer Inst. 97, 247-248 (2005).
5. John EM, Hopper JL, Beck JC et al.: The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res. 6, R375-R389 (2004).
6. Lipshutz RJ, Fodor SP, Gingeras TR, Lockhart DJ: High density synthetic oligonucleotide arrays. Nat. Genet. 21, 20-24 (1999).
7. Parrish ML, Wei N, Duenwald S et al.: A microarray platform comparison for neuroscience applications. J. Neurosci. Method 132, 57-68 (2004).
8. Nuwaysir EF, Huang W, Albert TJ et al.: Gene expression analysis using oligonucleotide arrays produced by maskless photolithography. Genome Res. 12, 1749-1755 (2002).
9. Baurn M, Bielau S, Rittner N et al.: Validation of a novel, fully integrated and flexible microarray benchtop facility for gene expression profiling. Nucleic Acids Res. 31, e151 (2003).
10. Gao X, LeProust E, Zhang H et al.: A flexible light-directed DNA chip synthesis gated by deprotection using solution photogenerated acids. Nucleic Acid Res. 29, 4744-4750 (2001).
11. Dorris DR, Nguyen A, Gieser L et al.: Oligodeoxyribonucleotide probe accessibility on a three-dimensional DNA microarray surface and the effect of hybridization time on the accuracy of expression ratios. BMC Biotechnol. 3, 6 (2003).
12. Gunderson KL, Kruglyak S, Graige MS et al.: Decoding randomly ordered DNA arrays. Genome Res. 14, 870-877 (2004).
13. Brown PO, Botstein D: Exploring the new world of the genome with DNA microarrays. Nat. Genet. 21, 33-37 (1999).
14. Taniguchi M, Miura K, Iwao, H, Yamanaka S: Quantitative assessment of DNA microarrays - comparison with Northern blot analyses. Genomics 71, 34-39 (2001).
15. Ishii M, Hashimoto S, Tsutsumi S et al.: Direct comparison of GeneChip and SAGE on the quantitative accuracy in transcript profiling analysis. Genomics 68, 136-143 (2000).
16. Ramakrishnan R, Dorris D, Lubtinsky A et al.: An assessment of Motorola Codelink microarray performance for gene expression profiling applications. Nuc. Acids Res. 30, e30 (2002).
17. Ma XJ, Wang Z, Ryan PD et al.: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5, 607-616 (2004).
18. Reid JF, Lusa L, De Cecco L et al.: Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J. Natl Cancer Inst. 97, 927-930 (2005).
19. Mah N, Thelin A, Lu T et al.: A comparison of oligonucleotide and cDNA-based microarray systems. Physiol Genomics 16, 361-370 (2004).
20. Kothapalli R, Yoder SJ, Mane S, Loughran TP Jr: Microarray results: how accurate are they? BMC Bioinformatics 3, 22 (2002).
21. Tan PK, Downey TJ, Spitznagel EL Jr et al: Evaluation of gene expression measurements from commercial microarray platforms. Nuc. Acids Res. 31, 5676-5684 (2003)
22. Kuo WP, Jenssen T-K, Butte AJ, Ohno-Machado L, Kohane IS: Analysis of matched mRNA measurements from two different microarray technologies. Bioinform, 18, 405-412 (2002).
23. Rogojina AT, Orr WE, Song BK, Geisert EE Jr: Comparing the use of Affymetrix to spotted oligonucleotide microarrays using two retinal pigment epithelium cell tines. Mol. Vis. 9, 482-496 (2003).
24. Miklos GL, Maleszka R: Microarray reality checks in the context of a complex disease. Nat. Biotechnol. 22, 615-621 (2004).
25. Lee JK, Bussey KJ, Gwadry FG et al.: Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells. Genome Biol. 4, R82 (2003).
26. Mecham BH, Klus GT, Strovel J et al: Sequence-matched probes produce increased cross-platform consistency and more reproducible biological results in microarray-based gene expression measurements. Nuc. Acids Res. 32, e74 (2004).
27. Yuen T, Wurmbach E, Pfeffer RL, Ebersole BJ, Sealfon SC: Accuracy and calibration of commercial oligonucleotide and custom cDNA microarrays. Nuc. Acid Res. 30, e48 (2002).
28. Jarvinen AK, Hautaniemi S, Edgren H et al.: Are data from different gene expression microarray platforms comparable? Genomics 83, 1164-1168 (2004).
29. Barczak A, Rodriguez MW, Hanspers K et al.: Spotted long oligonucleotide arrays for human gene expression analysis. Genome Res. 13, 1775-1785 (2003).
30. Brazma A, Hingamp P, Quackenbush J et al.: Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat. Genet. 29, 365-371 (2001).
31. Culhane AC, Perriere G, Higgins DG: Cross-platform comparison and visualisation of gene expression data using co-inertia analysis. BMC Bioinformatics 4, 59(2003).
32. Novoradovskaya N, Whitfield ML, Basehore LS et al.: Universal Reference RNA as a standard for microarray experiments. BMC Genomics 5, 20 (2004).
33. Kuo WP, Liu F, Trimarchi J et al.: A sequence-oriented comparison of gene expression measurements across different hybridization-based technologies. Nat. Biotechnol. 24, 832-840 (2006).
34. Shi L, Reid LH, Jones VM et al.; the MAQC Consortium: The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol. 24, 1151-1161 (2006).
35. Sorlie T, Tibshirani R, Parker J et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100, 8418-8423 (2003).
36. Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM: Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res. 62, 4427-4433 (2002).
37. Alizadeh AA, Eisen MB, Davis RE et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511 (2000).
38. Shipp MA, Ross KN, Tamayo P et al.: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. 8, 68-74 (2002).
39. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM: A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc. Natl Acad. Sci. USA 100, 9991-9996 (2003).
40. Wang Y, Jatkoe T, Zhang Y et al.: Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J. Clin. Oncol. 22, 1564-1571 (2004).
41. Wang Y, Klijn JG, Zhang Y et al.: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365, 671-679 (2005).
42. Simon R: Development and validation of therapeutically relevant multi-gene biomarker classifiers. J. Natl. Cancer Inst. 97, 866-867 (2005).
43. Ransohoff, D. Rules of evidence for cancer molecular-marker discovery and validation. Nat. Rev. Cancer 4, 309-314 (2004).
44. van de Vijver MJ, He YD, van't Veer LJ et al.: A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
45. van 't Veer LJ, Dai H, van de Vijver MJ et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
46. Ransohoff DF: Gene-expression signatures in breast cancer. N. Engl. J. Med. 348, 1715-1717 (2003)
47. Huang E, Cheng SH, Dressman H et al.: Gene expression predictors of breast cancer outcomes. Lancet 361, 1590-1596 (2003)
48. Chang JC, Wooten EC, Tsimelzon A et al.: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362, 362-369 (2003).
49. Rosenwald A, Wright G, Chan WC et al.: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 1937-1947 (2002).
50. Foekens JA, Atkins D, Zhang Y et al.: Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J. Clin. Oncol. 24, 1665-1671 (2006).
51. Tibshirani R, Hastie T, Narasimhan B, Chu G: Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc. Natl. Acad. Sci. USA 99, 6567-6572 (2002).
52. Smid M, Wang Y, Klijn JG et al.: Genes associated with breast cancer metastatic to bone. J Clin. Oncol. 24, 2261-2267 (2006).
53. Lossos IS, Czerwinski DK, Alizadeh AA et al.: Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N. Engl. J. Med. 350, 1828-1837 (2004).